
Less Drug, Same Result?
On November 14, 2026, a paper in The Lancet Diabetes & Endocrinology landed with a headline number that made the obesity-drug crowd do a double take. Novo Nordisk's investigational CagriSema, tested at doses well below the ones in its FDA filing, produced roughly 21% average weight loss at 68 weeks. The full data were then presented at ObesityWeek 2026 in Washington, DC, which ran November 14 to 17.
Here is what the trial actually found, what it does not prove, and why a two-peptide combo is the most interesting thing in the GLP-1 world right now. ๐
What CagriSema Is
CagriSema pairs two molecules in one weekly injection: semaglutide, a GLP-1 agonist, and cagrilintide, an amylin analog. Novo's own press release describes it as "a GLP-1 and amylin analog." You can read the full profile on our CagriSema page.
The logic is simple. Hit two different appetite pathways instead of one, and you might get more out of the combination than either gives alone. That is exactly the pitch behind most next-generation obesity drugs, and it is why retatrutide and others are stacking mechanisms too.
The REDEFINE 9 Trial
REDEFINE 9 was a 68-week, placebo-controlled Phase 3 trial. It enrolled 309 adults without diabetes who had obesity (BMI of 30 or higher), or overweight (BMI of 27 or higher) with at least one obesity-related complication. Everyone also got lifestyle counseling.
Participants were randomized to one of three groups:
- CagriSema at 1.7 mg of each drug (104 people)
- CagriSema at 1.0 mg of each drug (103 people)
- Pooled placebo (102 people)
Novo says this is the first Phase 3 weight-management trial of CagriSema at doses below 2.4 mg/2.4 mg. That is the dose in the company's FDA application. Per MedicalXpress's write-up of the paper, the trial ran at 24 sites across Canada, France, Germany, the U.K. and the U.S. About 77% of participants were women, the average age was 48, and the average starting weight was 109.5 kg.
The Numbers
At week 68, using the "efficacy estimand" (what happens if people stay on treatment), average weight loss was:
- 20.7% on the 1.7 mg/1.7 mg dose
- 21.0% on the 1.0 mg/1.0 mg dose
- 2.0% on placebo
Using the "treatment-regimen estimand," which counts everyone regardless of whether they stopped treatment or used rescue medication, the numbers were 19.4%, 18.6% and 4.6%. Waist circumference dropped by 17.2 cm and 17.5 cm on CagriSema, versus 3.6 cm on placebo.
That second set of numbers is the more conservative real-world read, and it is still close to 19%. The headline 21% is the best-case "everyone sticks with it" version. Both are worth knowing, and any article that only quotes one is cherry-picking.
Does the Lower Dose Really Work Just as Well?
Careful here. The lower dose did not beat the higher dose, and the two are basically tied. But Novo states the trial was not powered to detect differences between the two CagriSema doses. So "equal" is not a proven conclusion. It means the study did not show a gap, which is a weaker statement.
On tolerability, permanent discontinuation due to adverse events was 2.9% on the 1.7 mg dose and 4.9% on the 1.0 mg dose, versus 4.9% on placebo. Novo says the safety profile matched earlier CagriSema trials, with gastrointestinal side effects the most common, mostly mild to moderate. That is a company statement, and the small numbers mean you should not read much into the gap between the two doses.
The authors themselves say the dose options may support more flexible, individualized treatment, and that larger and more diverse trials are needed. The population here was small and not very diverse. Fair enough.
Where CagriSema Stands With the FDA
CagriSema is not approved in the U.S. Novo filed a New Drug Application with the FDA in December 2025 for the 2.4 mg/2.4 mg dose for weight management, and the company says a decision is expected in the fourth quarter of 2026. We are in mid-November, so that window is closing fast.
Note what is being reviewed: the higher dose. REDEFINE 9 is not the basis for that filing. It is a data point about what lower doses might do later.
For context, the earlier REDEFINE 1 trial randomized 3,417 adults and was published in the New England Journal of Medicine in 2025. REDEFINE 9 is a much smaller study, so treat it as a supporting piece, not a replacement.
How to Read a Number Like "21%"
Weight-loss headlines are slippery, so here is a quick filter we use on every trial write-up.
First, check which estimand the number comes from. The gap between 21.0% and 18.6% in this very trial is the difference between "people who stayed on drug" and "everyone who signed up." Neither is wrong, but they answer different questions.
Second, check the comparison. Placebo lost 2.0% to 4.6% depending on the method, so the treatment difference is smaller than the raw figure and also depends on which estimand you pick.
Third, check who sponsored the numbers and who reviewed them. Here the trial is peer-reviewed in a major journal, which counts for something, but most of the coverage still leans on Novo's own press materials. Keep your skepticism calibrated, not cynical.
Finally, remember the difference between a drug that has human trial data and a compound that only has animal studies. CagriSema is firmly in the first group, which is rare in the peptide world. Plenty of popular research compounds are still waiting for that kind of evidence, and honest coverage should say so.
The Bigger Picture for Peptide Fans
Step back and notice what the biggest drugmaker in obesity is spending its billions on. A combination of two peptides, one of them an amylin analog, injected weekly. Peptide science is not the fringe here. It is the mainstream, and the research community has been tracking these compounds for years while the headlines caught up.
If you want to see how this combo lines up against the others, our comparison pages are the fastest route: semaglutide vs CagriSema, retatrutide vs CagriSema and CagriSema vs cagrilintide. You can browse everything in our peptide database or the full compare tool.
Bottom Line
REDEFINE 9 is a solid, well-run trial that suggests CagriSema works at lower doses than the one under FDA review. It is not proof that lower is just as good, it is a modest 309-person study, and the company's own press release is the main source for most of the figures. The real test is the FDA decision expected this quarter.
This article is educational, not medical advice.
Sources
Researching peptides? Track your protocols free.
Pro members save 10% on every shop order, all year, with no cap.
Topics covered:
Enjoyed this article?
Get an email when we publish a new guide, when something sold out is back, or when a price drops.